|
6 Apr 2023
Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research
…
|
|
10 Feb 2023
Genentech To Expand Next-Generation Manufacturing Network With New Oceanside Facility
…
|
|
25 Jan 2023
Genentech Statement on FDA Oncologic Drug Advisory Meeting on March 9, 2023
…
|
|
9 Dec 2022
FDA Approves Genentech’s Tecentriq as First-Ever Therapy for a Certain Advanced Rare Sarcoma
…
|
|
7 Dec 2022
Genentech Confirms Sufficient Nationwide Supply Available of Xofluza and Tamiflu for Pharmacies to Order
…
|
|
28 Nov 2022
Genentech Provides Update on Tecentriq U.S. Indication for Previously Untreated Metastatic Bladder Cancer
…
|
|
26 Sep 2022
Genentech and Partners Launch New Open-source Curriculum to Bring Biotechnology Education to Millions of High School Students
…
|
|
19 Aug 2022
Genentech Opens Clinical Supply Center for Next-generation Biologics Manufacturing
…
|
|
27 Jul 2022
Update on Actemra® (tocilizumab) Supply in the U.S.
…
|
|
23 Jun 2021
Genentech Launches Oncology Clinical Trial Diversity Alliance
…
|
|
12 Mar 2021
Genentech Statement on FDA Oncologic Drug Advisory Meetings on April 27–29, 2021
…
|
|
14 Dec 2020
Genentech Statement On Most Favored Nation Interim Final Rule
…
|
|
11 May 2020
Genentech and the Genentech Foundation Commit $42 Million to Address Immediate and Long-Term Effects of the COVID-19 Pandemic
…
|
|
11 Mar 2020
Genentech Statement on COVID-19
…
|
|
11 Sep 2019
Genentech Congratulations 2019 Lasker Award Laureates
…
|
|
30 Aug 2019
Genentech Provides Update on Supplemental Biologics License Application (sBLA) for Tecentriq in First-Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
…
|
|
19 Aug 2019
Retirement of Dr. Sandra Horning & Appointment of Dr. Levi Garraway to Chief Medical Officer, Roche and Genentech
…
|
|
19 Mar 2019
Genentech Provides Update on Venclexta Multiple Myeloma Program
…
|
|
1 Feb 2019
An Open Letter to the Hemophilia Community Regarding Patient Access to Hemlibra (emicizumab-kxwh)
…
|
|
24 Jan 2019
Genentech Announces Alexander Hardy As Chief Executive Officer
…
|
|
5 Sep 2018
Genentech Provides Update on Supplemental Biologics License Application (SBLA) for Tecentriq in First-Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
…
|
|
5 Feb 2018
Genentech Works to Expand Patient Access to Tamiflu During the 2017-2018 Flu Season
…
|
|
9 Nov 2017
Genentech Statement on Chroma, the Second Phase III Study for Lampalizumab
…
|
|
14 Dec 2016
Genentech Announces Bill Anderson As Chief Executive Officer
Genentech, a member of the Roche Group, today announced the appointment of Bill Anderson to chief executive officer, effective January 1, 2017…
|
|
27 Feb 2016
Genentech Statement on Two-Year Protocol T Trial Data in Ophthalmology
Protocol T Two-Year Results Published Today…
|
|
10 Feb 2016
Tamiflu 2015-16 Flu Season Supply
Based upon our current forecasts, we anticipate having sufficient supply of both Tamiflu® (oseltamivir phosphate) formulations (oral suspension and capsules) for the 2015-16 flu season…
|
|
17 Jul 2015
Genentech Statement On Updated ATS Guidelines
Esbriet Is Recommended In The American Thoracic Society’s (ATS) Idiopathic Pulmonary Fibrosis (IPF) Treatment Guidelines
New clinical practice guidelines recommend Esbriet® (pirfenidone) for…
|
|
22 May 2015
Nutropin AQ® [somatropin (rDNA origin) injection]
Counterfeiting of Nutropin AQ…
|
|
18 Feb 2015
Genentech Statement on Protocol T Trial Data in the New England Journal of Medicine
The Diabetic Retinopathy Clinical Research Network’s (DRCR.net) Comparative Effectiveness Protocol T Study was published today in the New England Journal of Medicine…
|
|
11 Apr 2014
Response to Cochrane’s Review of Tamiflu Clinical Data
We fundamentally disagree with the overall conclusions of the Cochrane Acute Respiratory Infection Group’s (ARI) report on Tamiflu® (oseltamivir phosphate). We firmly stand by the quality and…
|
|
14 Oct 2013
Genentech Disappointed with CA Governor's Veto of Patient Access to Biosimilars Bill
We will continue to work with the California legislature and state governments across the country to ensure safe access to biosimilar products…
|
|
8 Aug 2013
FDA Advisory Committee to review Genentech’s Perjeta regimen for use before surgery in HER2-positive early stage breast cancer
Genentech today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will discuss the company's application for use of a Perjeta®(pertuzumab)…
|
|
11 Feb 2013
Genentech Statement on Counterfeit Drug Labeled as Altuzan (Bevacizumab) in the United States
Roche and Genentech have been informed that the U.S. Food and Drug Administration (FDA) has discovered additional counterfeit product that has been distributed by a U.S. company, Medical Device King (…
|
|
4 Apr 2012
Genentech Statement on Counterfeit Drug Labeled as Altuzan (Bevacizumab) in the United States
Roche and Genentech have been informed that the U.S. Food and Drug Administration (FDA) has discovered additional counterfeit product that has been purchased by medical practices in the United States…
|
|
14 Feb 2012
Genentech Statement on Counterfeit Drug Labeled as Avastin® (Bevacizumab) in the United States
Roche and Genentech have been informed that a counterfeit product, labeled as Avastin (bevacizumab), has been distributed in the United States…
|
|
28 Apr 2011
Genentech Statement on CAT Trial Data Published in the New England Journal of Medicine
Today’s publication of the CAT Trial results in the New England Journal of Medicine provides important information regarding two treatments for wet age-related macular degeneration (AMD). Based upon…
|
|
2 Jun 2010
Update On Phase III Study With Avastin In Aggressive Non-Hodgkin's Lymphoma
Genentech, Inc., a member of the Roche Group, today announced it has accepted the recommendation of an independent Data and Safety Monitoring Board (DSMB) to stop enrollment into the MAIN trial, a…
|
|
27 May 2010
FDA Advisory Committee To Review Supplemental Biologics License Applications For Avastin For Metastatic Breast Cancer
Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will discuss the…
|
|
11 Dec 2009
Genentech Announces Study Of Avastin In Early-Stage Breast Cancer (E5103) Will Resume Enrollment And Continue As Planned
Genentech, Inc., a member of the Roche Group, has been informed that the U.S. Food and Drug Administration (FDA) is allowing enrollment to resume into a Phase III clinical trial (E5103) evaluating…
|
|
9 Mar 2009
FDA Advisory Committee To Review Supplemental Biologics License Application For Accelerated Approval O Avastin For Previously Treated Glioblastoma
Genentech, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will discuss the company's supplemental Biologics License Application (sBLA…
|